SCHEMBL6986004

SCHEMBL6986004

O=C(O)c1cnc2c3c(ccc2c1)C(=O)CC=N3

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 4/20 0.44
MGAM O43451 1/20 0.39
STAMBP O95630 2/20 0.32
COPS5 Q92905 2/20 0.32
P4HA1 P13674 2/20 0.32
P4HTM Q9NXG6 2/20 0.32
HCAR3 P49019 1/20 0.31
MIF P14174 1/20 0.31
MAPT P10636 2/20 0.30
KDM4E B2RXH2 1/20 0.30
KDM6B O15054 1/20 0.30
TET3 O43151 1/20 0.30
KDM4A O75164 1/20 0.30
BBOX1 O75936 1/20 0.30
ALDH1A1 P00352 1/20 0.30
KDM5A P29375 1/20 0.30
KDM5C P41229 1/20 0.30
ASPH Q12797 1/20 0.30
KDM4D Q6B0I6 1/20 0.30
TET2 Q6N021 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1087851 0.78 PSMD14 (0.64) PSMD14MGAMSTAMBPCOPS5P4HA1
SCHEMBL31058237 0.78 PSMD14 (0.64) PSMD14MGAMSTAMBPCOPS5P4HA1
SCHEMBL6981270 0.75 PSMD14 (0.43) PSMD14MGAMSTAMBPCOPS5P4HA1
SCHEMBL6985187 0.72 PSMD14 (0.40) PSMD14MGAMHCAR3ALDH1A1
SCHEMBL28173369 0.70 MGAM (0.62) PSMD14MGAM
SCHEMBL14649419 0.69 CCR1 (0.66) PSMD14MGAMSTAMBPCOPS5P4HA1
SCHEMBL2718836 0.68 PSMD14 (0.53) PSMD14MGAMSTAMBPCOPS5P4HA1
SCHEMBL21358078 0.68 PSMD14 (0.60) PSMD14MGAMSTAMBPCOPS5MAPT
SCHEMBL1416297 0.67 PSMD14 (0.51) PSMD14MGAMSTAMBPCOPS5P4HA1
SCHEMBL6984771 0.66 PSMD14 (0.43) PSMD14STAMBPCOPS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP claimed
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 PSMD14 4321/4885MGAM 4170/4885STAMBP 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.